SCHEMBL9928581

SCHEMBL9928581

COc1ccc(/C=C/CCc2ccc(OC)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.57
KDM4E B2RXH2 2/20 0.57
LMNA P02545 1/20 0.57
TP53 P04637 1/20 0.57
TSHR P16473 1/20 0.57
ALDH1A1 P00352 1/20 0.57
TRPA1 O75762 1/20 0.50
RELA Q04206 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50
RAB9A P51151 2/20 0.49
CYP1A2 P05177 3/20 0.48
ESR1 P03372 2/20 0.48
CYP1A1 P04798 2/20 0.48
CYP1B1 Q16678 2/20 0.48
ABL1 P00519 1/20 0.48
TTR P02766 1/20 0.48
ABCB1 P08183 1/20 0.48
ALOX5 P09917 1/20 0.48
BCR P11274 1/20 0.48
CYP19A1 P11511 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16784200 0.91 TRPA1 (0.59) CYP3A4KDM4ELMNATP53TSHR
SCHEMBL31197199 0.91 TRPA1 (0.59) CYP3A4KDM4ELMNATP53TSHR
SCHEMBL29850441 0.91 CYP3A4 (0.52) CYP3A4KDM4ELMNATP53TSHR
SCHEMBL30543062 0.91 CYP3A4 (0.52) CYP3A4KDM4ELMNATP53TSHR
SCHEMBL9954880 0.89 SLC6A4 (0.46) CYP3A4KDM4ELMNATP53TSHR
SCHEMBL9954884 0.89 SLC6A4 (0.46) CYP3A4KDM4ELMNATP53TSHR
SCHEMBL9005279 0.81 TAAR1 (0.53) CYP3A4KDM4ELMNATP53TSHR
SCHEMBL13181157 0.81 KDM4E (0.55) CYP3A4KDM4ELMNATP53TSHR
SCHEMBL11429370 0.81 CYP3A4 (0.57) CYP3A4KDM4ELMNATP53TSHR
SCHEMBL12479217 0.81 KDM4E (0.55) CYP3A4KDM4ELMNATP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149769-A1 Thiocarbonates as Anti-Inflammatory and Antioxidant Compounds Useful For Treating Metabolic Disorders GENMEDICA THERAPEUTICS SL (ES) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149769-A1 Thiocarbonates as Anti-Inflammatory and Antioxidant Compounds Useful For Treating Metabolic Disorders CPT1B, LTC4S, TXNRD2 CYP3A4 4247/4885KDM4E 4746/4885LMNA 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.